Q3 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$320M+33.7% YoY

Gross Profit

$200M62.5% margin

Operating Income

$112M35.1% margin

Net Income

$132M41.2% margin

EPS (Diluted)

$1.88

QoQ Revenue Growth

-0.5%

Cash Flow

Operating Cash Flow

$117M

Free Cash Flow

$102M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$823M

Stockholders' Equity

$699M

Cash & Equivalents

$614M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$320M	$239M	+33.7%
Gross Profit	$200M	$147M	+35.6%
Operating Income	$112M	$86M	+31.0%
Net Income	$132M	$61M	+115.5%

Revenue Segments

Product

$320M34%

Radiopharmaceutical Oncology

$216M23%

PYLARIFY

$215M23%

Total Precision Diagnostics

$96M10%

DEFINITY

$67M7%

Techne Lite

$23M2%

Strategic Partnerships And Other

$7M1%

Other Precision Diagnostics

$6M1%

Other Radiopharmaceutical Oncology

$848,0000%

License and Royalty Revenues

$438,0000%